Hal Barron, GlaxoSmithKline’s top scientist and architect of the company’s plans to revitalize its drug research, will step down from his role later this year …

The findings are a huge disappointment for Adagio, which billed ADG20 as a weapon that could neutralize a wide range of variants and help with …

AstraZeneca is betting that Ionis’ second drug for transthyretin amyloidosis, or ATTR, will stand out where its first one couldn’t. Ionis developed Tegsedi for years …

A vaccine against RSV has proven elusive despite decades of attempts. Pfizer is moving at a surprisingly quick pace to catch up to rivals led …

Drugmakers have laboured for decades to successfully develop a vaccine to protect infants and older people against infections of a common pathogen called respiratory syncytial …

Benlysta’s approval was itself a landmark, being the first such drug approved in decades. Its use has grown slowly and steadily over time, falling just …